Literature DB >> 12105193

Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin.

Michael J Duggan1, Conrad P Quinn, John A Chaddock, John R Purkiss, Frances C G Alexander, Sarah Doward, Sarah J Fooks, Lorna M Friis, Yper H J Hall, Elizabeth R Kirby, Nicola Leeds, Hilary J Moulsdale, Anthony Dickenson, G Mark Green, Wahida Rahman, Rie Suzuki, Clifford C Shone, Keith A Foster.   

Abstract

Clostridial neurotoxins potently and specifically inhibit neurotransmitter release in defined cell types. Here we report that a catalytically active derivative (termed LH(N)/A) of the type A neurotoxin from Clostridium botulinum has been coupled to a lectin obtained from Erythrina cristagalli to form a novel conjugate. This conjugate exhibits an in vitro selectivity for nociceptive afferents compared with the anatomically adjacent spinal neurons, as assessed using in vitro primary neuronal culture systems to measure inhibition of release of neurotransmitters. Chemical conjugates prepared between E. cristagalli lectin and either natively sourced LH(N)/A or recombinant LH(N)/A purified from Escherichia coli are assessed, and equivalence of the recombinant material are demonstrated. Furthermore, the dependence of inhibition of neurotransmitter release on the cleavage of SNAP-25 is demonstrated through the use of an endopeptidase-deficient LH(N)/A conjugate variant. The duration of action of inhibition of neurotransmitter released by the conjugate in vitro is assessed and is comparable with that observed with Clostridium botulinum neurotoxin. Finally, in vivo electrophysiology shows that these in vitro actions have biological relevance in that sensory transmission from nociceptive afferents through the spinal cord is significantly attenuated. These data demonstrate that the potent endopeptidase activity of clostridial neurotoxins can be selectively retargeted to cells of interest and that inhibition of release of neurotransmitters from a neuronal population of therapeutic relevance to the treatment of pain can be achieved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105193     DOI: 10.1074/jbc.M202902200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  The changed image of botulinum toxin.

Authors:  V Peter Misra
Journal:  BMJ       Date:  2002-11-23

2.  The impatient patient: a personal view of osteoarthritis.

Authors:  Michael C Powanda
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

3.  Structures of engineered Clostridium botulinum neurotoxin derivatives.

Authors:  Geoffrey Masuyer; Patrick Stancombe; John A Chaddock; K Ravi Acharya
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-11-25

4.  Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.

Authors:  K A Foster; E J Adams; L Durose; C J Cruttwell; E Marks; C C Shone; J A Chaddock; C L Cox; C Heaton; J M Sutton; J Wayne; F C G Alexander; D F Rogers
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 5.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 6.  [Potential antinociceptive mechanisms of botulinum toxin].

Authors:  K R Aoki; J Francis; W H Jost
Journal:  Schmerz       Date:  2006-09       Impact factor: 1.107

7.  Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.

Authors:  Sabine Pellett; William H Tepp; Larry H Stanker; Philip A Band; Eric A Johnson; Konstantin Ichtchenko
Journal:  Biochem Biophys Res Commun       Date:  2011-02-01       Impact factor: 3.575

Review 8.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

9.  Engineering botulinum neurotoxin to extend therapeutic intervention.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-01       Impact factor: 11.205

Review 10.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.